Drugs / CTM Boost
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06160427 | Dec 2023 → Jan 2027 expected | tendinitis, tendinosis | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06712290 | Nov 2024 → Dec 2025 | rotator cuff syndrome | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTM Boost | “CTM Boost (CTM Biomedical, Miami, FL) is a tissue allograft derived from decellularized, particulate human placental connective tissue.” NCT06712290 ↗ |
| Known as | CTM | “Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue.” NCT06160427 ↗ |
| Modality | Other / unclassified | “It is considered a minimally-manipulated biologic by the FDA” NCT06160427 ↗ |
| Route | Other | “It is administered via injection.” NCT06160427 ↗ |